monomethyl-auristatin-e and carfilzomib

monomethyl-auristatin-e has been researched along with carfilzomib* in 1 studies

Other Studies

1 other study(ies) available for monomethyl-auristatin-e and carfilzomib

Article	Year
Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes. Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:8 Carfilzomib (CFZ) is a proteasome inhibitor used for oncology indications including treating multiple myeloma. CFZ is a potent cytotoxic agent with an IC Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cathepsin B; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Feasibility Studies; Humans; Immunoconjugates; Lysosomes; Neoplasms; Oligopeptides; Receptor, ErbB-2; Sialic Acid Binding Ig-like Lectin 2	2019

Article

Year

Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.

Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:8

Carfilzomib (CFZ) is a proteasome inhibitor used for oncology indications including treating multiple myeloma. CFZ is a potent cytotoxic agent with an IC

Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cathepsin B; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Feasibility Studies; Humans; Immunoconjugates; Lysosomes; Neoplasms; Oligopeptides; Receptor, ErbB-2; Sialic Acid Binding Ig-like Lectin 2

2019